Take the pledge to vote

For a better tommorow#AajSawaroApnaKal
  • I agree to receive emails from News18

  • I promise to vote in this year's elections no matter what the odds are.
  • Please check above checkbox.

    SUBMIT

Thank you for
taking the pledge

Vote responsibly as each vote counts
and makes a diffrence

Disclaimer:

Issued in public interest by HDFC Life. HDFC Life Insurance Company Limited (Formerly HDFC Standard Life Insurance Company Limited) (“HDFC Life”). CIN: L65110MH2000PLC128245, IRDAI Reg. No. 101 . The name/letters "HDFC" in the name/logo of the company belongs to Housing Development Finance Corporation Limited ("HDFC Limited") and is used by HDFC Life under an agreement entered into with HDFC Limited. ARN EU/04/19/13618
CO-PRESENTED BY
LIVE TV DownloadNews18 App
News18 English
272
nda:
Needmore seats to Win
Needmore seats to Win
upa:
»
2-min read

China's Fosun Pharma to Buy Smaller Stake in Indian Firm for $1.1Billion

Shanghai Fosun Pharmaceutical Group had previously sought an 86 percent stake valued at about $1.26 billion, but the deal had raised concerns among some in New Delhi.

Reuters

Updated:September 17, 2017, 9:55 PM IST
facebookTwittergoogleskypewhatsapp
China's Fosun Pharma to Buy Smaller Stake in Indian Firm for $1.1Billion
In this file photo, a company logo is pictured at the headquarters of Shanghai Fosun Pharma Group in Shanghai, China on September 13, 2016. (Photo: Reuters/Aly Song)
Loading...
Beijing /Mumbai: Shanghai Fosun Pharmaceutical Group has agreed to cut the size of the stake it will buy in India's Gland Pharma to 74 percent, it said on Sunday, paying about $1.1 billion for what is still set to be China's biggest acquisition in India.

Fosun had previously sought an 86 percent stake valued at about $1.26 billion, but the deal had raised concerns among some in New Delhi, a source told Reuters.

Rules issued in June stipulate that foreign investors can buy equity stakes of up to 74 percent in India's pharmaceutical companies without requiring government approval.

Fosun did not mention regulatory hurdles in its statement to the stock exchange, noting only that Gland Pharma's founding family wanted to retain a bigger holding in the Indian company because of its good performance.

But Gland managing director Ravi Penmetsa told Reuters that the companies had applied for anti-trust approval in the United States and certain other approvals in China that were at risk of expiring.

"Now with this new agreement, we won't have to reapply for those," he said, adding that he expects the deal to be completed in two weeks.

The new deal will cap Fosun's investment at $1.09 billion. Fosun Pharma also said it would spend no more than $25 million to market the Indian company's enoxaparin blood-thinning drug in the United States, when it obtains approval there, cutting the previously proposed marketing spend by half.

Gland added that the deal would see it manufacture some of Fosun's biosimilar drugs for the Indian market. These are cheaper copies of complex biotech drugs that require specialised manufacturing capabilities and command much higher prices than regular generics.

Sunday's statement said that Gland would be able to make the biosimilars at Fosun's site and sell them in India.

"It won't happen overnight, but we have started working on it," Penmetsa said.

The deal will also give Gland better access to markets such as Africa, where it currently sells through third parties, Penmetsa said.

Penmetsa and his father, P.V.N. Raju, will remain on the Gland board and the current management team will continue to run the company.
(Get detailed and live results of each and every seat in the Lok Sabha elections and state Assembly elections in Andhra Pradesh, Odisha, Arunachal Pradesh and Sikkim to know which candidate/party is leading or trailing and to know who has won and who has lost and by what margin. Our one-of-its-kind Election Analytics Centre lets you don a psephologist’s hat and turn into an election expert. Know interesting facts and trivia about the elections and see our informative graphics. Elections = News18)
| Edited by: Bijaya Das
Read full article
Loading...
Next Story
Next Story

Also Watch

facebookTwittergoogleskypewhatsapp
 
 
Most Active
Company Price Change %Gain
ICICI Bank 431.75 5.09
Reliance 1,336.85 0.22
SBI 355.35 3.84
IndusInd Bank 1,648.90 3.14
Larsen 1,544.15 4.61
Company Price Change %Gain
GRUH Finance 313.30 -4.42
Reliance 1,336.80 0.07
Larsen 1,543.65 4.60
SpiceJet 141.55 9.64
SBI 354.60 3.59
Top Gainers
Company Price Change %Gain
ICICI Bank 431.75 5.09
Larsen 1,544.15 4.61
Zee Entertain 376.85 4.55
JSW Steel 288.00 4.37
Bharti Airtel 353.20 4.25
Company Price Change %Gain
ICICI Bank 431.50 5.09
Larsen 1,543.65 4.60
Bharti Airtel 353.30 4.40
Vedanta 163.85 4.20
Tata Motors 182.15 4.09
Top Losers
Company Price Change %Gain
Tech Mahindra 735.85 -1.00
NTPC 129.15 -0.54
TCS 2,048.00 -0.29
HUL 1,749.60 -0.24
HCL Tech 1,065.95 -0.04
Company Price Change %Gain
NTPC 129.20 -0.54
HCL Tech 1,061.65 -0.46
TCS 2,049.65 -0.20
HUL 1,749.20 -0.10

Live TV

Loading...
Countdown To Elections Results
  • 01 d
  • 12 h
  • 38 m
  • 09 s
To Assembly Elections 2018 Results